Mosquito-inoculated sporozoite stages of the parasite invade the liver and undergo an intracellular replication phase in hepatocytes to produce merozoite stages, which initiate the erythrocytic cycle responsible for the pathology of malaria [2] . The growth and replication of liver stages is not associated with any clinical symptoms and in humans requires ∼7 days, which provides a good target for anti-infection immune responses. Indeed, immunization with whole live parasites completely protects against the initial hepatic stage. In mammals, this was first shown using rodent malaria irradiationattenuated sporozoite immunizations, which induced protection against challenge with infectious sporozoites [3] . The irradiated sporozoite rodent malaria models have made critical contributions to our understanding of the basic immune mechanisms that mediate sterile 
countries is staggering, killing millions each year [1] . Mosquito-inoculated sporozoite stages of the parasite invade the liver and undergo an intracellular replication phase in hepatocytes to produce merozoite stages, which initiate the erythrocytic cycle responsible for the pathology of malaria [2] . The growth and replication of liver stages is not associated with any clinical symptoms and in humans requires ∼7 days, which provides a good target for anti-infection immune responses. Indeed, immunization with whole live parasites completely protects against the initial hepatic stage. In mammals, this was first shown using rodent malaria irradiationattenuated sporozoite immunizations, which induced protection against challenge with infectious sporozoites [3] . The irradiated sporozoite rodent malaria models have made critical contributions to our understanding of the basic immune mechanisms that mediate sterile protection against infection [4, 5] . The success of the experimental sporozoite vaccine model led to trials with irradiated sporozoites of Plasmodium falciparum. The trials demonstrated complete and long-lasting sterile protection in humans as well [6] , indicating that protection by vaccination with live attenuated sporozoites is a universal principle. A vaccine based on a single protein component of sporozoites-the circumsporozoite protein (CSP) of P. falciparum-has undergone extensive clinical testing [7] but has not achieved complete protection. Recently it was proposed that because attenuated sporozoites remain the only fully protective experimental vaccine, their large-scale development and licensure as a deployable malaria vaccine should be pursued [8] . Gamma irradiation causes random damage to DNA and, when correctly dosed, allows sporozoites to maintain their infective properties [9, 10] . DNA damage, however, likely results in cell-cycle arrest of the replicating liver stage and, thus, in aborted development early during infection [10] . Inactivated sporozoites alone are not protective [11] , which shows that biological functionality during the initial stages of sporozoite infection is critical for the induction of protection. Furthermore, in P. berghei, the persistence of intrahepatocytic parasites is necessary for the maintenance of long-lasting protection [12] . Using the P. berghei model, we have recently shown that deletion of the single-copy genes UIS3 and UIS4 leads to specific defects in early parasite liver-stage development in in vitro hepatocyte infections [13, 14] . These studies and other work [15] showed that attenuation of the malaria parasite by precise genetic manipulation is possible (genetically attenuated Plasmodium parasites [GAPs] ). Immunization of mice with P. berghei GAPs leads to complete protection against subsequent infectious sporozoite challenge [13] [14] [15] .
To further study GAP infections in vivo and to compare the protective efficacy of distinct GAPs, we constructed UIS3 and UIS4 deletions in the P. yoelii rodent malaria parasite (Pyuis3 [Ϫ] and Pyuis4 [Ϫ] ). P. yoelii is highly infectious to BALB/c mice, exhibiting a low ID 50 of !10 sporozoites [16, 17] . This models the high infectivity of P. falciparum sporozoites for humans [18] better than the P. berghei model, which requires at least 10 times more sporozoites to infect mice [16] . Hence, P. yoelii is arguably a more relevant model for malaria vaccine studies. Here, we show that P. yoelii GAP vaccines do not persist in the liver of immunized mice but confer sterile protection for at least 6 months. GAP-mediated protection is strictly dependent on CD8 + T cells. Our studies also reveal that differences in the protective efficacy of distinct GAP vaccines are made apparent when single-dose immunization regimens are used.
MATERIALS AND METHODS

Experimental animals and cell lines. Female Swiss Webster
(SW) and BALB/c mice (6-8 weeks old) for in vivo infection experiments were purchased from Harlan, and BALB/c mice (6-8 weeks old) for immunization experiments were purchased from Jackson Laboratories. Animal handling was conducted in accordance with Institutional Animal Care and Use Committee-approved protocols. P. yoelii 17 XNL (a nonlethal strain) clone 1.1, Pyuis3(Ϫ), and Pyuis4(Ϫ) parasites were cycled between Anopheles stephensi mosquitoes and SW mice. Infected mosquitoes were maintained on sugar water at 24ЊC and 70% humidity. Hepa1-6 (ATCC CRL-1830) and HepG2:CD81 [27] hepatoma cells were used for in vitro assays.
Generation of Pyuis3(5) and Pyuis4(5) parasites. Deletions of PyUIS3 and PyUIS4 were performed by constructing replacement plasmids in vector b3D.DT.H Db (provided by Dr. A. Waters, Leiden University, Leiden, The Netherlands) containing the pyrimethamine-resistant Toxoplasma gondii dhfr/ts gene. Using oligonucleotide primers PY3REP1 forward (F) and PY3REP2 reverse (R), a 500-bp fragment was amplified encoding the 5 untranslated region (UTR) of PyUIS3, and a similar-sized fragment encoding the 3 UTR was amplified using PY3REP3F and PY3REP4R primers with P. yoelii genomic DNA as the template (table 1 shows oligonucleotide primer sequences used in the study). Two fragments were amplified using primers PY4REP1F and PY4REP2R for the 1-kb fragment containing the 5 UTR sequence and PY4REP3F and PY4REP4R for the 600-bp fragment containing the 3 UTR sequence of PyUIS4, with P. yoelii genomic DNA as template. The 5 UTR fragments were cloned into the KpnI and HindIII sites of the vector. The 3 UTR fragments were cloned into the EcoRI and BamHI sites. The resulting plasmids were digested with KpnI and XbaI to release the replacement fragment used for transfection. Replacement knockout parasites, as indicated above, are referred to as "Pyuis3(Ϫ)" and "Pyuis4(Ϫ)" GAPs. Transfections (Nucleofector device; Amaxa), selection, and cloning by limited dilution of Pyuis3(Ϫ) and Pyuis4(Ϫ) parasites were performed as described elsewhere [19] . For genotypic analysis, genomic DNA was extracted from blood-stage parasites using the DNeasy kit (Qiagen). To demonstrate the replacement of PyUIS3 or PyUIS4 in the transformed parasite, we used the following sets of oligonucleotide primers (table 1) . Test 1 was demonstrated using dihydrofolate reductase-thymidilate synthase (DHFR-TS) forward [13] with PY3REP4R or PY4REP4R; test 2 replacement was demonstrated using DHFR-TS forward [13] with PY3REP5R or PY4REP5R; wild-type (wt) contamination was demonstrated using PY3RTF and PY3RTR primers for PyUIS3 and PY4RTR and PY4RTR primers for PyUIS4; episomal contamination was assessed using T7 [13] with PY3REP3F or PY4REP3F.
To evaluate transcript expression, mosquitoes infected with wt, Pyuis3(Ϫ), and Pyuis4(Ϫ) sporozoites were col- 6 1 ϫ 10 lected at day 14 after a blood meal. RNA was extracted using Trizol (Invitrogen) and treated with DNase (Invitrogen). Firststrand cDNA was synthesized using Superscript (Invitrogen) and used as template for polymerase chain reaction (PCR) using PY3RTF/PY3RTR and PY4RTF/PY4RTR sets of oligonucleotide primers (table 1) .
Phenotypic analysis of Pyuis3(5) and Pyuis4(5) parasites in mosquito and hepatoma cells. A. stephensi mosquitoes were infected with Pyuis3(Ϫ) and Pyuis4(Ϫ) parasites and control wt parasites by blood-feeding on infected SW mice. Infected mosquitoes were dissected at days 10 and 14 after the blood meal to determine the degree of infection (by analysis of midgut oocyst load) and the mean number of sporozoites per salivary gland (using a hemocytometer). To demonstrate host cell entry by sporozoites, the sporozoite inside/outside indirect immunofluorescence assay (IFA) was performed [20] using Hepa 1-6 cells and anti-CSP (2F6) antibody in combination with Alexa Fluor 594 (red) and Alexa Fluor 488 (green) secondary antibodies. Sporozoites were counted using a fluorescence-inverted microscope (Eclipse TE2000-E; Nikon).
In vivo Plasmodium liver stage development. For in vivo infections, sporozoites were injected by intravenous (iv) 6 3 ϫ 10 tail injection into BALB/c mice. Livers were harvested at different time points, and the left and median lobes were fixed in 4% paraformaldehyde and then cut into 50-mm sections using a vibratome (Ted Pella). The sections were immunostained with mouse monoclonal antibodies (MAbs) against P. yoelii CSP (2F6), heat-shock protein (HSP) 70 [21] , and HEP17 [22] , as well as rabbit polyclonal antibodies against UIS4 [13] and MTIP [23] . Quantification of liver stages at the 2-24-h Figure 2 . Plasmodium yoelii Pyuis3 (Ϫ) and Pyuis4 (Ϫ) sporozoites lacking defects in mosquito salivary gland infection and mammalian host cell invasion. A, Histogram of mean ‫ע‬ SD nos. of salivary gland sporozoites/mosquito, obtained at day 14 after feeding for wild-type (wt)-, Pyuis3 (Ϫ)-, and Pyuis4 (Ϫ)-infected mosquitoes from 5 independent experiments. B, Reverse-transcriptase (RT) polymerase chain reaction analysis using locus-specific oligonucleotide primers showing that PyUIS3 or PyUIS4 transcripts are absent in the respective knockout sporozoites. +, RT added; Ϫ, RT not added. C, Hepatocyte invasion in Pyuis3 (Ϫ) and Pyuis4(Ϫ) sporozoites. Shown are the mean ‫ע‬ SD proportions of sporozoites located inside Hepa1-6 hepatoma cells using the inside/outside staining assay.
time points was performed by microscopically counting the number of liver stages with CSP antibody staining observed in 10 sections, each 50 mm thick, of the left lobe of the infected liver. Late liver stages were quantified using the same method with antibodies against HSP70 and merozoite surface protein (MSP) 1.
Total RNA was extracted from remaining lobes of the liver using Trizol and treated with Turbo-free DNase (Ambion) to remove genomic DNA. First-strand cDNA was synthesized from 500 ng of total RNA using the Superscript III Platinum RT kit. For PCR, cDNA equivalent to 25 ng of RNA was used for each reaction using the P. yoelii 18S rRNA and mouse GAPDH primers. Real-time PCR analysis was performed on ABI prism 7300 Sequence Detection Systems using the SYBR Green PCR Master Mix (Applied Biosystems).
Immunization and challenge experiments. BALB/c mice were injected iv with 50,000 or 10,000 Pyuis3(Ϫ) or Pyuis4(Ϫ) sporozoites. Booster injections were administered 2 weeks apart. The immunized mice were challenged by iv injection with 10,000 wt sporozoites. Blood-stage infection was determined by the presence of parasites in Giemsa-stained blood smears prepared daily from days 3 to 15 after challenge.
T cell depletion experiments. For in vivo depletion of CD4 + or CD8 + T cells, immune mice were injected intraperitoneally daily, 7 days before challenge, with either 1-mg doses of anti-CD4 MAb GK1.5 (TIB207; American Type Culture Collection), 0.5-mg doses of anti-CD8 MAb 2.43 (TIB210; American Type Culture Collection), or equivalent doses of control rat IgG, as described elsewhere [24] . The dose and regimens used in this experiment had been previously optimized for obtaining 195% of depletion efficiency in mice (data not shown).
Sporozoite neutralization assay. A total of 50,000 green fluorescent protein-tagged P. yoelii parasites were preincubated with 2F6 antibody against CSP or serum from mice immunized with uninfected mosquito extract (mock) or P. yoelii GAP sporozoites. The preincubated sporozoites were then added to subconfluent HepG2:CD81 cells that were seeded in 8-well chambered slides (Nunc) and maintained at 37ЊC in 5% CO 2 . Cells were incubated for 44 h, after which they were trypsinized and subjected to fluorescence-activated cell sorting.
RESULTS
Generation and life cycle characterization of Pyuis3(5) and Pyuis4(5) GAPs. Targeted disruptions of the PyUIS3 and PyUIS4 loci were performed using a replacement strategy with double homologous recombination ( figure 1A) . After transfection of parasites, drug selection, and cloning of resistant parasites by limiting dilution, correct gene replacement in clonal parasite populations was confirmed by PCR typing using gene replacement-specific oligonucleotide primers (figure 1B). Pyuis3(Ϫ) and Pyuis4(Ϫ) parasites were indistinguishable from wt parasites with regard to blood-stage replication, gametocyte formation, exflagellation of male gametes, transmission to mosquitoes, and midgut oocyst sporozoite development (data not shown). The salivary gland sporozoite loads of mosquitoes infected with Pyuis3(Ϫ) and Pyuis4(Ϫ) GAPs were similar to those of wtinfected mosquitoes at day 14 after feeding, which indicated normal salivary gland infection capacity ( figure 2A ). The lack Reduced GAP parasite nos. are detected in infected livers at 2 h after infection, subsequently decrease in no., and are not detectable at 40 h after infection. Note that wt liver stages are exhibiting an apparent initial reduction in parasite nos., but nos. appear to be similar 12 h after infection and at later time points. B, Injection of wt and P. yoelii GAP sporozoites into mice. After 40 6 3 ϫ 10 h, livers were harvested and subjected to total RNA extraction and realtime polymerase chain reaction using primers specific for P. yoelii 18S rRNA and mouse GAPDH. The relative liver stage burden is calculated as the ratio of the no. of copies of P. yoelii 18S rRNA and mouse GAPDH.
of PyUIS3 and PyUIS4 transcripts was confirmed by reversetranscription PCR analysis using RNA obtained from the Pyuis3(Ϫ) and Pyuis4(Ϫ) salivary gland sporozoites (figure 2B).
We next examined, using a cell entry assay in Hepa1-6 cells, whether Pyuis3(Ϫ) and Pyuis4(Ϫ) sporozoites were able to initiate the invasion of host cells. No differences were observed in the proportion of intracellular sporozoites when we compared the Pyuis3(Ϫ) and Pyuis4(Ϫ) sporozoites with wt sporozoites (figure 2C), which indicates that sporozoite host cell entry is not affected in GAPs.
Liver infection defects and in vivo persistence of Pyuis3(5) and Pyuis4(5) GAPs. To compare the liver infection and liver-stage development of wt parasites and GAPs in vivo, we injected sporozoites each iv into BALB/c mice and har- 6 3 ϫ 10 vested livers for tissue sectioning at different time points after infection. Indirect IFAs of fixed liver sections using antibodies against CSP and UIS4 were used to locate liver stages for quantification and analysis. We observed a 75% and 60% reduction in the number of liver stages of Pyuis3(Ϫ) and Pyuis4(Ϫ) GAPs, respectively, at 2 h after infection ( figure 3A) . The numbers of GAP liver stages detected in sections 24 h after infection were reduced by 195%, compared with wt sections. GAPs were not detectable in sections obtained 40 h after infection ( figure 3A) . In addition, quantitative real-time PCR using total RNA isolated from livers infected with GAPs (300ϫ the effective 6 3 ϫ 10 immunization dose) at 40 h after infection did not detect significant parasite persistence (figure 3B).
Pyuis3(Ϫ) and Pyuis4(Ϫ) liver stages were morphologically similar to wt liver stages at 6 and 12 h after infection, a time when the intrahepatocytic transformation from elongate sporozoite to spherical trophozoites commences (figure 4A and 4B). Importantly, antibody staining of Pyuis3(Ϫ) liver stages for UIS4, a resident parasitophorous vacuole membrane (PVM) protein, showed a typical circumferential pattern, which indicates that the PVM is present in these GAP (figure 4). Pyuis4(Ϫ) liver stages of course did not stain for UIS4, but we confirmed the presence of a PVM using an antibody against another resident PVM protein, HEP17 (data not shown).
At 24 h after infection, wt liver stages had developed to the schizont stage, notable by their significant growth and progression of nuclear divisions. By contrast, the few detected Pyuis3(Ϫ) and Pyuis4(Ϫ) liver stages remained small and appeared to be arrested at the trophozoite stage ( figure 4C ). As mentioned, these arrested GAP liver stages did not persist in the liver. In addition to CSP, UIS4, and HEP17 staining, staining of infected liver sections 40 h after infection with antibodies against MSP1 and HSP70 did not reveal any detectable GAPs in the liver at time points 140 h after infection (data not shown).
Induction of sterile protection by Pyuis3(5) and Pyuis4(5) GAPs. We next performed a series of immunization/challenge experiments using different regimens to assess the immune protection conferred by Pyuis3(Ϫ) and Pyuis4(Ϫ) GAPs (table  2) . None of the mice immunized with P. yoelii GAP sporozoites shown in table 2 developed blood-stage infection after immunization. Each challenge experiment was performed with parallel naive mouse controls, which developed blood-stage patency 3-4 days after sporozoite challenge (data not shown). A single immunization of BALB/c mice with 50,000 Pyuis3(Ϫ) sporozoites did not confer protection against challenge with 10,000 wt sporozoites 7 days after the immunization. Two immunizations with 10,000 Pyuis3(Ϫ) sporozoites were needed to achieve complete protection. Strikingly, a single immunization of BALB/c mice with 50,000 Pyuis4(Ϫ) sporozoites con- ferred complete protection against challenge with 10,000 wt sporozoites 7 days after immunization. This protection was sustained at first challenge, 30 days after immunization.
We next determined how long GAP-induced protection is sustained. A triple-immunization regimen of BALB/c mice with 10,000 Pyuis4(Ϫ) sporozoites conferred complete protection against challenge with 10,000 wt sporozoites 60 and 180 days after the last immunization. However, although a triple-immunization regimen of BALB/c mice with 10,000 Pyuis3(Ϫ) sporozoites conferred complete protection against challenge with 10,000 wt sporozoites 60 days after the last immunization, it protected 66% of the immunized mice against a challenge 180 days after the last immunization. Together, these results indicate that genetically distinct GAPs show significant differences in their protective efficacy that can be distinguished with variable-dose immunizations and timing of challenge.
T cell depletion as an indication of a major role for CD8 + T cells in GAP-induced protective immunity. To determine the effector T cells involved in the Pyuis3(Ϫ) and Pyuis4(Ϫ) GAP-induced protection against wt sporozoite challenge, 3-dose immunization experiments were done. Beginning 7 days after the last immunization, the BALB/c mice were injected with consecutive doses of anti-CD4 + MAbs, anti-CD8 + MAbs, or rat IgG as a negative control. All treated mice and naive control mice were challenged with 10,000 wt sporozoites 14 days after the last immunization. Mice depleted of CD8 + T cells became blood-stage patent 1 day later than naive mice (mice that did not receive a GAP vaccine). CD4 + T cell-depleted mice remained completely protected, as did mice that received the IgG control ( figure 5A and 5B). Thus, in 2 P. yoelii GAP-BALB/ c models, sterile protection against high-dose sporozoite challenge was dependent on effector CD8 + but not CD4 + cells. The 1-day delay in patency seen in CD8 + T cell-depleted mice suggests that anti-sporozoite antibodies may also have a protective effect. In an in vitro hepatoma cell infection assay, we observed that preincubation of infectious sporozoites with P. yoelii GAP immune serum caused a significant decrease in infection, compared with infections with sporozoites preincubated in mockimmunized serum ( figure 5C ). Immune serum from P. yoelii GAP-immunized mice showed reactivity with sporozoites in IFA ( figure 5D ).
DISCUSSION
Sterile protection against sporozoite-induced malaria infection across a range of Plasmodium species/host combinations is only achieved by vaccination with live attenuated sporozoites [3, 6, 25, 26] . Here, we used the P. yoelii-BALB/c model to explore the use of GAPs as live vaccines.
Deletion of the UIS3 and UIS4 locus in P. yoelii generated Pyuis3(Ϫ) and Pyuis4(Ϫ) parasite lines that each showed specific defects only in productive liver infection and therefore appeared to be phenotypically similar to our P. berghei GAPs described elsewhere [13, 14] . However, the high infectivity of P. yoelii sporozoites in BALB/c mice [16, 19] allowed us to examine the persistence of GAPs in vaccinated mice quantitatively. Furthermore, to our knowledge, we provide the first data on GAP protective efficacy against sporozoite challenge in the P. yoelii-BALB/c model. This model's sporozoite infectivity profile [16] resembles that of P. falciparum more closely than P. berghei and has the additional advantage of exhibiting a specific hepatocyte tropism, which is not observed in P. berghei infection [27] . Pyuis3(Ϫ) and Pyuis4(Ϫ) sporozoites showed no defect in host cell entry in vitro; however, evaluation of Pyuis3(Ϫ) and Pyuis4(Ϫ) GAP liver infections and comparison with wt liver infection showed that Pyuis3(Ϫ) and Pyuis4(Ϫ) GAPs were present in significantly reduced numbers as early as 2 h after iv sporozoite injection. We currently do not know whether this is owing to some insufficiency in initial liver infection such as sporozoite extravasation by Kupffer cell traversal [28] or to a subsequent rapid die-off of intrahepatocytic P. yoelii GAPs and their host hepatocytes. The Pyuis3(Ϫ) and Pyuis4(Ϫ) GAPs that entered hepatocytes formed an apparently normal PVM compartment in vivo. This contrasts with recent findings using P. berghei P36p(Ϫ) GAPs [15] . Those parasites showed a deficiency in PVM formation and, thus, were free in the hepatocyte cytoplasm. P36p(Ϫ) GAP-infected hepatocytes underwent apoptosis, which provides a possible explanation for fast P36p(Ϫ) GAP clearance from in vitro-infected hepatoma cells [15] . However, their in vivo clearance in the livers of infected mice was not determined. Our analysis of liver infections at later time points revealed that Pyuis3(Ϫ) and Pyuis4(Ϫ) GAPs developmentally arrested at the trophozoite stage and showed no discernible phenotypic differences. Furthermore, Pyuis3(Ϫ) and Pyuis4(Ϫ) GAPs showed no significant persistence beyond 40 h after infection as evaluated by IFA and confirmed by quantitative PCR. It will be of interest to examine whether GAP-infected hepatocytes undergo programmed cell death or death by necrosis. A preliminary analysis revealed no evidence of caspase 3 activation in Pyuis3(Ϫ) and Pyuis4(Ϫ) GAP-infected hepatocytes in vitro and in vivo (data not shown), which indicates that caspase-mediated apoptotic cell death is not a major contributor, but mechanisms involved in clearance need further detailed investigation.
Intriguingly, immunization with P. yoelii GAPs conferred complete protection against a first challenge after 6 months, which indicates that maintenance of immunological memory does not depend on GAP liver-stage persistence. However, it is of interest to note that effective protection by radiationattenuated parasites was shown to depend on parasite forms that persisted in the liver for weeks to months [12] , but this work was done with P. berghei and may possibly reflect a phenomenon specific to this species. In addition, in the P. berghei model it has been observed that, after sporozoite transmission by mosquito bite, exoerythrocytic-like parasite forms are found in the skin and lymphatic system of infected mice [29] . Whether such parasite forms persist in the P. yoelii model and, as a result, form an extrahepatic antigenic reservoir remains to be determined. Sterile protection by Pyuis3(Ϫ) and Pyuis4(Ϫ) GAPs was absolutely dependent on CD8 + T cells-their depletion effectively rendered all tested mice susceptible to infectious sporozoite challenge. Depletion of CD4 + T cells did not reverse protection. Although infection-blocking anti-sporozoite antibodies are induced after P. yoelii GAP immunization, they are clearly not sufficient to confer sterile protection. Thus, effector mechanisms other than CD8 + T cell-mediated elimination of parasites are inadequate for complete protection in these P. yoelii GAP-BALB/c models. Concerning this, our findings reveal a similar mechanism for GAP-mediated protection and radiation-attenuated sporozoite-mediated protection of BALB/c mice [30] .
We have shown that a single-dose Pyuis4(Ϫ) GAP vaccine completely protects BALB/c mice against massive challenge with 10,000 wt sporozoites. Reported single-dose vaccination using P. yoelii radiation-attenuated sporozoites [31] did not achieve complete protection against a similar-dose challenge, but vaccination of mice receiving chloroquine treatment with wt infectious sporozoites achieved protection with a single immunization [31] . Therefore, some GAP vaccines may have efficacy superior to that of irradiation-attenuated sporozoites, at least in the P. yoelii-BALB/c model. However, conclusive evidence supporting this must come from a direct experimental comparison of GAPs and irradiation-attenuated sporozoite efficacy studies. The genetically dissimilar Pyuis3(Ϫ) GAP required a minimum of 2 immunizations with 10,000 sporozoites to achieve complete protection. This finding demonstrates that GAP vaccines have distinct potencies.
In conclusion, our data provide evidence that GAPs are superb vaccines offering complete, long-lasting protection in a mouse malaria model. Therefore, the search for an optimally attenuated P. falciparum GAP should be initiated and may yield a single-dose malaria vaccine that confers complete, long-lasting protection against initial infection. Although, selection, production, and deployment of a live attenuated malaria vaccine faces many formidable obstacles [32] , it may ultimately provide the only opportunity to completely protect humans against malaria infection by vaccination.
